Mesa Laboratories INC /CO/

Mesa Laboratories, Inc. has amended and restated its Code of Ethics and Business Conduct, effective immediately, to modernize policies on external communications and social media.

Mesa Laboratories, Inc. has appointed Lyndsey Crennen as its new Chief Accounting Officer, effective June 26, 2026.

Mesa Laboratories announced fourth quarter and full fiscal year 2026 results, highlighting revenue growth, increased operating income, and significant debt repayment.

Mesa Laboratories, Inc. announced CEO Gary Owens' departure, effective April 13, 2026, with a transition agreement and immediate board resignation.

Mesa Laboratories reports strong third fiscal quarter 2026 results with a 3.6% revenue increase and a significant 317% rise in net income, driven by robust BPD growth and cost realignment benefits.

Mesa Laboratories announced a 5.0% revenue increase and 34.7% operating income growth in Q2 FY26, driven by strong performance in BPD and CS, despite challenges in Clinical Genomics China.

Mesa Laboratories, Inc. announced a significant turnaround in net income for the third quarter and nine months ended December 31, 2025, driven by revenue growth and improved operating efficiency, despite ongoing challenges in its Clinical Genomics division in China.

Mesa Laboratories reports 5% revenue growth in Q2 2025, but net income declined 27.8% due to China challenges and increased operating expenses, while strategic cost cuts are underway.

Mesa Laboratories reports a 2.4% revenue increase to $59.5 million in Q1 FY26, but operating income fell 45.1% due to higher expenses and lower gross margins, despite a boost from foreign currency gains.

Mesa Laboratories reports a 17.5% increase in revenue for Q3 2025, driven by the GKE acquisition and organic growth in several divisions, but discloses a material weakness in IT general controls.

Mesa Laboratories' second quarter results show revenue growth driven by the GKE acquisition, but also reflect challenges in the Clinical Genomics division and increased interest expenses.

Mesa Laboratories' first quarter of fiscal year 2025 saw a significant increase in revenue and operating income, boosted by the acquisition of GKE and organic growth in key divisions.

Mesa Laboratories, a global leader in life sciences tools, reported an 11.5% increase in total revenues for fiscal year 2025, driven by organic growth and the GKE acquisition, while successfully managing its debt obligations and remediating prior year internal control weaknesses.

Mesa Laboratories Inc. releases its annual 10-K filing, outlining its business strategy, segment performance, and financial results for the fiscal year ended March 31, 2024.

Mesa Laboratories Inc. reports a Form 4 filing detailing the sale of common stock by SVP Operations Brian Archbold.

Mesa Laboratories CAO Lyndsey Crennen sold 118 shares of common stock to cover taxes on vested RSUs, with the transaction occurring on June 16, 2026.

Mesa Laboratories CFO John Sakys sold 1,223 shares of common stock to cover taxes related to RSU vesting, while also reporting indirect beneficial ownership of 50 shares held for his children.

Brian Archbold, SVP Operations at Mesa Laboratories Inc., reported a transaction involving the sale of common stock and the acquisition of Restricted Stock Units.

Mesa Laboratories CFO John Sakys reported transactions involving common stock, stock options, and restricted stock units.

Mesa Laboratories Inc. reports that President and CEO Siddhartha Kadia acquired 35,236 Restricted Stock Units (RSUs) on April 14, 2026.

Mesa Laboratories, Inc. announces its 2026 Annual Meeting of Shareholders, detailing director nominations, auditor ratification, and executive compensation advisory vote.

Mesa Laboratories, Inc. announced its 2025 Annual Meeting of Shareholders, highlighting significant fiscal year 2025 achievements including revenue growth, successful GKE integration, and debt restructuring, alongside proposals for director elections and an equity incentive plan amendment.

Mesa Laboratories will hold its annual shareholder meeting on August 30, 2024, to vote on director elections, auditor ratification, and executive compensation.

Long Path Smaller Companies Fund, LP and affiliated entities report a beneficial ownership of 8.6% in Mesa Laboratories, Inc. following an amendment to their Schedule 13G filing.

Long Path Smaller Companies Fund, LP and affiliated entities report a beneficial ownership of 7.3% in Mesa Laboratories, Inc. as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Mesa Laboratories Inc. following an internal corporate realignment.

Long Path Smaller Companies Fund and its affiliates have reported a 5.6% beneficial ownership stake in Mesa Laboratories, Inc., totaling 311,703 shares.

The Vanguard Group has reported a 5.84% beneficial ownership stake in Mesa Laboratories Inc., holding 321,717 common shares as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.9% beneficial ownership of Mesa Laboratories Inc.'s common stock as of September 30, 2025.